SpyBiotech Company
SpyBiotech Operators of a biotechnology platform intended to generate next-generation vaccines.The company's biotechnology platform develops bonding vaccines which are made from the proprietary protein superglue which is used to bond antigens to viruses and other particles to make vaccines, enabling medical institutions and research centers with a new and modified technology to develop vaccines which give better results in lesser time.
Total Funding:
37490885
Headquarters:
Oxford, Oxfordshire, United Kingdom
Funding Status:
Early Stage Venture
Estimated Revenue:
Less than $1M
Last Funding Type:
Series A
Last Funding Date:
2021-02-10
Investors Number:
5
Founded Date:
2017-01-01
Industry:
Atrificial Vectors and Immune Cells